| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| von Willebrand Factor | 11 | 2024 | 192 | 2.790 |
Why?
|
| Multiple Myeloma | 11 | 2026 | 217 | 2.450 |
Why?
|
| Anatomy, Artistic | 3 | 2020 | 8 | 1.410 |
Why?
|
| Bacteriophages | 2 | 2021 | 100 | 1.000 |
Why?
|
| Factor VIII | 2 | 2015 | 51 | 0.860 |
Why?
|
| von Willebrand Diseases | 2 | 2022 | 55 | 0.850 |
Why?
|
| Blood Platelets | 4 | 2019 | 318 | 0.820 |
Why?
|
| von Willebrand Disease, Type 3 | 2 | 2024 | 6 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 580 | 0.690 |
Why?
|
| Oral and Maxillofacial Surgeons | 1 | 2020 | 1 | 0.680 |
Why?
|
| Endothelial Cells | 5 | 2019 | 531 | 0.610 |
Why?
|
| General Surgery | 2 | 2020 | 222 | 0.610 |
Why?
|
| Atlases as Topic | 1 | 2019 | 21 | 0.590 |
Why?
|
| Neurosurgeons | 1 | 2019 | 16 | 0.590 |
Why?
|
| Peripheral Nervous System | 1 | 2019 | 46 | 0.580 |
Why?
|
| Cervical Atlas | 1 | 2018 | 8 | 0.580 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2018 | 18 | 0.580 |
Why?
|
| Nerve Compression Syndromes | 1 | 2018 | 15 | 0.580 |
Why?
|
| Medical Illustration | 1 | 2018 | 18 | 0.580 |
Why?
|
| Neuralgia | 1 | 2018 | 51 | 0.550 |
Why?
|
| Neurosurgery | 1 | 2019 | 75 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1357 | 0.530 |
Why?
|
| Proteolysis | 4 | 2024 | 195 | 0.480 |
Why?
|
| Models, Cardiovascular | 2 | 2008 | 170 | 0.470 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2026 | 11 | 0.470 |
Why?
|
| B-Cell Maturation Antigen | 2 | 2026 | 13 | 0.460 |
Why?
|
| Smoldering Multiple Myeloma | 2 | 2026 | 5 | 0.440 |
Why?
|
| Thalidomide | 2 | 2025 | 41 | 0.430 |
Why?
|
| Surgeons | 1 | 2018 | 287 | 0.420 |
Why?
|
| Peptide Fragments | 2 | 2015 | 782 | 0.400 |
Why?
|
| Hemostasis | 1 | 2013 | 74 | 0.400 |
Why?
|
| Protein Multimerization | 1 | 2013 | 150 | 0.390 |
Why?
|
| Models, Molecular | 2 | 2018 | 1088 | 0.390 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2022 | 50 | 0.360 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2008 | 77 | 0.320 |
Why?
|
| Hemorrhage | 1 | 2013 | 499 | 0.320 |
Why?
|
| National Socialism | 2 | 2020 | 4 | 0.310 |
Why?
|
| Dissection | 2 | 2020 | 59 | 0.300 |
Why?
|
| Peripheral Nerves | 2 | 2020 | 89 | 0.300 |
Why?
|
| Holocaust | 2 | 2019 | 2 | 0.300 |
Why?
|
| Pulsatile Flow | 2 | 2008 | 112 | 0.280 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2026 | 962 | 0.280 |
Why?
|
| Humans | 39 | 2026 | 131967 | 0.280 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 2357 | 0.270 |
Why?
|
| History, 20th Century | 2 | 2019 | 366 | 0.260 |
Why?
|
| Fibrin | 2 | 2024 | 64 | 0.260 |
Why?
|
| Aged, 80 and over | 8 | 2026 | 6922 | 0.250 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 427 | 0.250 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 34 | 0.240 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 128 | 0.230 |
Why?
|
| Mind-Body Therapies | 1 | 2025 | 12 | 0.230 |
Why?
|
| Relaxation Therapy | 1 | 2025 | 24 | 0.230 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 240 | 0.220 |
Why?
|
| Aged | 11 | 2026 | 21279 | 0.220 |
Why?
|
| Nitric Oxide | 1 | 2008 | 467 | 0.220 |
Why?
|
| Bortezomib | 1 | 2025 | 74 | 0.220 |
Why?
|
| ADAM Proteins | 2 | 2015 | 84 | 0.220 |
Why?
|
| Immunization, Secondary | 1 | 2025 | 119 | 0.220 |
Why?
|
| Protein Structure, Quaternary | 2 | 2015 | 93 | 0.220 |
Why?
|
| Ikaros Transcription Factor | 1 | 2024 | 35 | 0.210 |
Why?
|
| Immunoconjugates | 1 | 2024 | 49 | 0.210 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2025 | 123 | 0.210 |
Why?
|
| Diarrhea | 1 | 2026 | 312 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2025 | 81 | 0.210 |
Why?
|
| Dexamethasone | 1 | 2025 | 262 | 0.200 |
Why?
|
| Pyrazoles | 1 | 2026 | 359 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 825 | 0.190 |
Why?
|
| NF-kappa B | 1 | 2025 | 450 | 0.190 |
Why?
|
| Abdomen | 1 | 2023 | 133 | 0.190 |
Why?
|
| Serpins | 1 | 2022 | 34 | 0.190 |
Why?
|
| ADAMTS13 Protein | 3 | 2018 | 66 | 0.190 |
Why?
|
| Middle Aged | 11 | 2026 | 28911 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2025 | 460 | 0.190 |
Why?
|
| Hemostatics | 1 | 2022 | 58 | 0.190 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2025 | 152 | 0.180 |
Why?
|
| Adult | 9 | 2025 | 31734 | 0.180 |
Why?
|
| Peptide Library | 3 | 2018 | 57 | 0.170 |
Why?
|
| Protein Biosynthesis | 2 | 2019 | 580 | 0.170 |
Why?
|
| Recurrence | 1 | 2025 | 1487 | 0.170 |
Why?
|
| Stress, Mechanical | 4 | 2010 | 179 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2025 | 564 | 0.160 |
Why?
|
| Treatment Outcome | 6 | 2026 | 13011 | 0.160 |
Why?
|
| Female | 14 | 2026 | 71316 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2026 | 1012 | 0.160 |
Why?
|
| Certification | 1 | 2020 | 72 | 0.150 |
Why?
|
| Mutation | 6 | 2024 | 6200 | 0.150 |
Why?
|
| Homozygote | 1 | 2021 | 549 | 0.150 |
Why?
|
| Platelet Adhesiveness | 1 | 2019 | 36 | 0.150 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2020 | 82 | 0.150 |
Why?
|
| Factor XII | 1 | 2018 | 4 | 0.150 |
Why?
|
| Metalloproteases | 1 | 2018 | 14 | 0.150 |
Why?
|
| World War II | 1 | 2018 | 6 | 0.150 |
Why?
|
| Mentoring | 1 | 2020 | 80 | 0.150 |
Why?
|
| Coronary Stenosis | 1 | 2019 | 77 | 0.140 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2018 | 5 | 0.140 |
Why?
|
| Acinetobacter baumannii | 1 | 2018 | 47 | 0.140 |
Why?
|
| Thrombosis | 1 | 2022 | 495 | 0.140 |
Why?
|
| Male | 12 | 2026 | 65357 | 0.140 |
Why?
|
| Thrombin | 1 | 2018 | 58 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 934 | 0.130 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 579 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 1790 | 0.120 |
Why?
|
| Whiplash Injuries | 1 | 2016 | 3 | 0.120 |
Why?
|
| Neck Pain | 1 | 2016 | 20 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2019 | 293 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 236 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 690 | 0.120 |
Why?
|
| Mutagenesis | 2 | 2015 | 335 | 0.120 |
Why?
|
| Cells, Cultured | 5 | 2008 | 2963 | 0.120 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 314 | 0.110 |
Why?
|
| Metalloendopeptidases | 1 | 2015 | 104 | 0.110 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 28 | 0.110 |
Why?
|
| Animals | 11 | 2024 | 34460 | 0.110 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 97 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2016 | 175 | 0.110 |
Why?
|
| Protein Stability | 1 | 2014 | 166 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 136 | 0.100 |
Why?
|
| Peptide Mapping | 1 | 2013 | 40 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2019 | 2573 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2016 | 164 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1264 | 0.100 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 943 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 194 | 0.100 |
Why?
|
| Kinetics | 3 | 2022 | 1105 | 0.100 |
Why?
|
| Binding Sites | 3 | 2024 | 1204 | 0.090 |
Why?
|
| DNA Primers | 1 | 2013 | 609 | 0.090 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2012 | 11 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 723 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 694 | 0.090 |
Why?
|
| Substrate Specificity | 3 | 2018 | 287 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2007 | 810 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 4762 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 812 | 0.080 |
Why?
|
| Metagenome | 1 | 2012 | 143 | 0.080 |
Why?
|
| Growth Plate | 1 | 2010 | 21 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1489 | 0.080 |
Why?
|
| Umbilical Veins | 2 | 2007 | 64 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2013 | 907 | 0.080 |
Why?
|
| Base Sequence | 1 | 2013 | 2783 | 0.080 |
Why?
|
| Spine | 1 | 2010 | 148 | 0.080 |
Why?
|
| Mice | 6 | 2019 | 18504 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 4058 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 904 | 0.070 |
Why?
|
| Shear Strength | 1 | 2008 | 17 | 0.070 |
Why?
|
| Disease Progression | 2 | 2026 | 2226 | 0.070 |
Why?
|
| United States | 2 | 2020 | 11827 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2014 | 3864 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2018 | 2566 | 0.070 |
Why?
|
| Intestines | 1 | 2012 | 592 | 0.070 |
Why?
|
| Bacteria | 1 | 2012 | 541 | 0.070 |
Why?
|
| Reactive Oxygen Species | 2 | 2007 | 520 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1281 | 0.060 |
Why?
|
| Blood Coagulation | 2 | 2018 | 132 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2007 | 312 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 227 | 0.060 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 60 | 0.060 |
Why?
|
| Prognosis | 2 | 2025 | 4961 | 0.060 |
Why?
|
| Nitriles | 1 | 2026 | 165 | 0.060 |
Why?
|
| NADPH Oxidases | 1 | 2005 | 108 | 0.060 |
Why?
|
| Mindfulness | 1 | 2025 | 29 | 0.060 |
Why?
|
| Inflammation | 2 | 2022 | 1500 | 0.060 |
Why?
|
| Phthalimides | 1 | 2024 | 3 | 0.050 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2024 | 3 | 0.050 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2024 | 7 | 0.050 |
Why?
|
| Piperidones | 1 | 2024 | 10 | 0.050 |
Why?
|
| Retreatment | 1 | 2024 | 87 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 175 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 185 | 0.050 |
Why?
|
| Morpholines | 1 | 2024 | 68 | 0.050 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2005 | 186 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2024 | 124 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2005 | 430 | 0.050 |
Why?
|
| Aorta | 1 | 2007 | 530 | 0.050 |
Why?
|
| Protein Binding | 2 | 2019 | 1712 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2006 | 681 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2022 | 83 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2024 | 220 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2026 | 445 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 85 | 0.050 |
Why?
|
| Vimentin | 1 | 2022 | 62 | 0.050 |
Why?
|
| Half-Life | 1 | 2022 | 151 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2022 | 43 | 0.050 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2022 | 39 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2025 | 437 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2022 | 166 | 0.050 |
Why?
|
| Cell Movement | 1 | 2005 | 886 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 269 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 388 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 1008 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 363 | 0.040 |
Why?
|
| Membranes, Artificial | 1 | 2001 | 27 | 0.040 |
Why?
|
| Microdialysis | 1 | 2001 | 59 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 192 | 0.040 |
Why?
|
| Collagen | 1 | 2022 | 289 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 701 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 738 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 3616 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 410 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2024 | 635 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 3415 | 0.040 |
Why?
|
| Viscera | 1 | 2019 | 55 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1141 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2019 | 71 | 0.040 |
Why?
|
| Expressed Sequence Tags | 1 | 1999 | 80 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2025 | 1174 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2018 | 27 | 0.040 |
Why?
|
| Gene Expression | 2 | 2005 | 1503 | 0.040 |
Why?
|
| Angioedemas, Hereditary | 1 | 2018 | 6 | 0.040 |
Why?
|
| Ribosomes | 1 | 2019 | 124 | 0.040 |
Why?
|
| Prothrombin Time | 1 | 2018 | 36 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 400 | 0.040 |
Why?
|
| Forecasting | 1 | 2020 | 361 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 2018 | 55 | 0.040 |
Why?
|
| Cochlea | 1 | 1999 | 88 | 0.040 |
Why?
|
| Transgenes | 1 | 2019 | 324 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2019 | 421 | 0.040 |
Why?
|
| Deafness | 1 | 1999 | 83 | 0.040 |
Why?
|
| Anxiety | 1 | 2025 | 1030 | 0.040 |
Why?
|
| Critical Illness | 1 | 2022 | 616 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2483 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 302 | 0.030 |
Why?
|
| Autografts | 1 | 2018 | 29 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 222 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2018 | 161 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2018 | 180 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2022 | 767 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 117 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 336 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 932 | 0.030 |
Why?
|
| Depression | 1 | 2025 | 1352 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 366 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 1319 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 53 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 910 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 551 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2015 | 98 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2019 | 819 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1165 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 6522 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 1812 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 2148 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2015 | 787 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2016 | 350 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 646 | 0.030 |
Why?
|
| Proteomics | 1 | 2018 | 614 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1078 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2020 | 1058 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 2154 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 811 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1261 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2012 | 58 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2012 | 58 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 1325 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2005 | 436 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2012 | 157 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 389 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 101 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2010 | 265 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4684 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3928 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3247 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2007 | 48 | 0.020 |
Why?
|
| Catalase | 1 | 2007 | 64 | 0.020 |
Why?
|
| Cell Shape | 1 | 2007 | 70 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 122 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2007 | 72 | 0.020 |
Why?
|
| Superoxides | 1 | 2007 | 129 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2007 | 117 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 179 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 2116 | 0.010 |
Why?
|
| Tropomyosin | 1 | 2005 | 26 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 2005 | 76 | 0.010 |
Why?
|
| Plasminogen Activators | 1 | 2005 | 19 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 3462 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 178 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2005 | 155 | 0.010 |
Why?
|
| Movement | 1 | 2005 | 149 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2005 | 659 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 336 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 832 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 1236 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 493 | 0.010 |
Why?
|
| Diffusion | 1 | 2001 | 59 | 0.010 |
Why?
|
| Calibration | 1 | 2001 | 95 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 17703 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 1999 | 121 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1841 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 4531 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 1069 | 0.010 |
Why?
|
| Hypertension | 1 | 2005 | 1362 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 6285 | 0.010 |
Why?
|